Infinity Pharmaceuticals Inc (INFI)

NASDAQ
1.190
0.000(0.00%)
After Hours
1.120
-0.070(-5.882%)
- Real-time Data
  • Volume:
    269,740
  • Day's Range:
    1.160 - 1.245
  • 52 wk Range:
    0.461 - 3.350
Unusual Post-Market activity

Post-market activity occurs after regular market hours and can be used to judge market strength and direction. Post-market trading has some risk because of lower liquidity and more volatility than regular sessions.

INFI Overview

Prev. Close
1.19
Day's Range
1.16-1.245
Revenue
2.22M
Open
1.17
52 wk Range
0.461-3.35
EPS
-0.525
Volume
269,740
Market Cap
106.24M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
533,897
P/E Ratio
-2.19
Beta
2
1-Year Change
-65.2%
Shares Outstanding
89,277,873
Next Earnings Date
Mar 14, 2023
What is your sentiment on Infinity?
or
Market is currently closed. Voting is open during market hours.

Infinity Pharmaceuticals Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Infinity Pharmaceuticals Inc Analysis

Infinity Pharmaceuticals Inc Company Profile

Infinity Pharmaceuticals Inc Company Profile

Employees
23

Infinity Pharmaceuticals, Inc. clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase 1/1b clinical study.

Read More

Analyst Price Target

Average6.071 (+410.20% Upside)
High11
Low3
Price1.19
No. of Analysts7
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellSellBuySell
Technical IndicatorsStrong SellStrong SellBuyStrong SellStrong Sell
SummaryStrong SellStrong SellNeutralNeutralStrong Sell
  • INFI (T) 1.4 3.5691
    0
    • Bought 2.47 going for double
      1
      • $9 by the end of this month
        10
        • Any more predcitions?
          0
      • any news ..updates?
        1
        • any news or updates...buy sell hold?
          0
          • offering at 3,80
            0
          • what does that mean
            0
        • what is the marketabiliity of the product to generate income?
          0
          • Why did I buy this....ugh.
            0